Funders and Partners

The DETECT-2 study is being led by the Women’s Precision Prevention clinical research team from the Wolfson Institute of Population Health, Queen Mary University London. This team is working in close partnership with researchers from Barts health NHS Trust, the London School of Hygiene and Tropical Medicine, University College London, University of Manchester, St Marks Hospital NHS trust, and Northwick Park Hospital.

DETECT-2 is supported by the Barts Clinical Trials Unit.

This study will be delivered by a network of cancer and research teams in NHS hospitals across the UK. For the list of collaborating sites and PIs click this link.

The study is funded by the GSK, the North East London Cancer Alliance, the North Central London Cancer Alliance and Barts Charity.

DETECT-2 is supported by a number of charity and patient representative groups including:

  1. Lynch Syndrome UK

  2. Ovarian Cancer Action

  3. BRCA Umbrella

  4. Target Ovarian Cancer

  5. The Eve Appeal